Rafael Holdings subsidiary, Cyclo Therapeutics is planning to submit a NDA to US regulators for Trappsol Cyclo in NPC despite the primary endpoint miss. Credit: Kateryna Kon / Shutterstock.com. Rafael ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results